News
Archive
Finally, Graphene electronic devices available for all
Ventyx Biosciences reports clinical data for its NLRP3 inhibitor portfolio and provides pipeline updates at virtual investor event
NorthSea Therapeutics initiates Phase 2A trial of Orziloben (NST-6179) in Intestinal Failure-Associated Liver Disease (IFALD)
Resolve Therapeutics announces publication of Lupus clinical trial results
biomodal delivers the 6-base genome with a powerful new multiomic solution, duet evoC
InvestEU in Belgium: EIB venture debt for bone therapy innovator Novadip
Back To NewsOctober 17, 2017
FlowCardia
Acquired by C.R. Bard. Developer of endovascular devices for the treatment of coronary and peripheral CTO.